A woman receives a dose of Sputnik V (Gam-COVID-Vac) vaccine against the coronavirus disease (COVID-19) at a vaccination center in a shopping mall in Saint Petersburg, Russia February 24, 2021. REUTERS FILE PHOTO
MOSCOW — A small-scale clinical study of the combined use of the AstraZeneca and Sputnik Light vaccines against COVID-19 has shown strong antibody growth in a majority of the study’s participants, the Russian Direct Investment Fund said on Monday.
The data was collected from 20 people who took part in a 100-person study in Azerbaijan that began in February. They first received the AstraZeneca shot followed by the one-dose Russian-made Sputnik Light shot 29 days later, RDIF said.
READ: Russia approves trials of combined AstraZeneca/Sputnik V vaccine
“According to the results of the interim analysis, a fourfold or higher increase in neutralising antibodies to the spike protein (S-protein) of the SARS-CoV-2 was found in 85% of the volunteers on the 57th day of the study,” RDIF said.